Detalhe da pesquisa
1.
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
J Immunol
; 198(1): 528-537, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27881707
2.
Assessing safety of extractables from materials and leachables in pharmaceuticals and biologics - Current challenges and approaches.
Regul Toxicol Pharmacol
; 81: 201-211, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27569203
3.
Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
J Immunol
; 199(5): 1943, 2017 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28827388
4.
Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys.
J Pharm Sci
; 102(1): 250-61, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23090886
5.
Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models.
Expert Opin Drug Discov
; 5(1): 79-94, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22823973